Change to the country's health care system will be smoother if current fraud and abuse laws are reformed to improve patient outcomes and reduce costs, according to a white paper released by the Healthcare Leadership Council.
The Food and Drug Administration (FDA) has accepted Celgene Corp.'s new drug application for Enasidenib, a treatment for patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation.
A recent SEARCH for Diabetes in Youth study found that teens and young adults with Type 2 diabetes are more likely to develop complications in the years following their diagnosis than their peers with Type 1 diabetes.
A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland.
Physicians have opposed the merger between Aetna and Humana for over a year and a half, trying to challenge the merger by giving the Department of Justice and state attorneys general evidence against the merger.
The U.S. Food and Drug Administration approved AbbVie’s IMBRUVICA for treatment of relapsed/refractory marginal zone lymphoma in patients who require systemic therapy and have received at least one prior anti-CD 20-based therapy.
The U.S. Food and Drug Administration recently reminded medical professionals nationwide that effective this week, the majority of powdered medical gloves will be banned from use following its regulation passed in December 2016.
In a revised approach to its plan with Arena Pharmaceuticals Inc. dating to November 2013, Eisai Inc. recently agreed to purchase all development and marketing rights for Arena’s weight loss treatment medication, lorcaserin hydrochloride CIV.
Advising health care facilities nationwide of possible safety defects in battery-operated mobile medical carts, the U.S. Food and Drug Administration recently issued a warning accompanied by guidance from its headquarters in Silver Spring, Maryland.
Adynovate by Shire was approved by the U.S. Food and Drug Administration last week for the treatment for hemophilia A in children under 12 years old and for use in surgical settings for both adult and pediatric patients.